All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stephanie Noviello, Jeong Heo et al.|The Lancet|2014Cited by 343
Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimensK. Rajender Reddy, Stephanie Noviello, Stanislas Pol et al.|Liver International|2017Cited by 24
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTSM.P. Manns, Stephanie Noviello, S. Pol et al.|Journal of Hepatology|2014Cited by 20
P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDYJia‐Horng Kao, M.P. Manns, June Heo et al.|Journal of Hepatology|2014Cited by 9